Internal Report 9: “449 Patients Suffer Bell’s Palsy Following Pfizer mRNA COVID Vaccination in Initial Three Months of Rollout. A One-Year-Old Endured Bell’s Palsy After Unauthorized Injection.”

The WarRoom/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1)—Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt—produced a disturbing review of the Facial Paralysis System Organ Class (SOC) adverse events found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB- 2021 (a.k.a., “5.3.6“). (https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf) This SOC includes facial paralysis and facial paresis, commonly known as Bell’s palsy. It is important to note that the adverse events (AEs) in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product. Key points in this report include:

• Facial paralysis and facial paresis diagnoses made up 1.07% of the total patient post-marketing population, or 449 total persons, reporting adverse events from December 1, 2020, to February 28, 2021.
• A one-year-old infant developed a Bell’s palsy one day after vaccination. It was unresolved at the time of the 5.3.6 report. The vaccine was not approved for use in children or infants at the time.
• 399 cases (88%) were classified as serious.
• Cases included: 295 (66%) female, 133 male (30%), and 21 (5%) not reported.
• Of events where time of onset was recorded, the time from vaccination to the adverse event becoming apparent ranged from within the first 24 hours to 46 days, with half of the facial events observed within two days.
• Only one clinical finding in these cases: damage to the 7th cranial nerve resulting in weakness or paralysis of the side of the face that is supplied by that nerve.
• Consequences of that nerve damage can include eye damage from inability to close the eyelid, impaired speech, impaired mouth closure (drooling) when eating.
• Pfizer identified that “. . . noninterventional post-authorisation safety studies, C4591011 and C4591012 are expected to capture data on a sufficiently large vaccinated population to detect an increased risk of Bell’s palsy in vaccinated individuals. The timeline for conducting these analyses will be established based on the size of the vaccinated population captured in the study data sources by the first interim reports (due 30 June 2021).”

Pfizer concluded: “This cumulative review does not raise new safety issues. Surveillance will continue.” However, since finalizing the 5.3.6 report at the end of February 2021, there has been no further summary data released for outside review. Furthermore, a search on https://clinicaltrials.gov/ for the cited studies (C4591011 and C4591012) yielded no studies found (accessed February 23, 2023). Please read this important report below.